Cancer and Immune Cell Metabolism in Patients With Hematological Malignancies

Recruiting now

Conditions studied: Hematologic Malignancy

In brief

This study investigates how metabolism in cancer and immune cells shapes the bone marrow environment, influences therapy resistance, and affects outcomes in hematological malignancies.

Key facts

Study ID

NCT07189117

Run by

University Hospital, Basel, Switzerland

People needed

350

Starts

2025-10-29

Expected to finish

2040-12-01

Last updated by the study team

2025-12-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• age > 18 years,
• signed written informed consent
• For participants with hematological cancers: diagnosis of MDS, AML, ALL, PMF or post-ET/PV MF

You may not qualify if…

• pregnant or lactating women,
• inability to give consent,
• active malignant disease (other than MDS, AML, ALL, PMF or post-ET/PV MF in the last 3 - years prior to study inclusion).
• For healthy donors: previous or current hematological disease, previous or current other malignant disease,

Where it is running

• University Hospital Basel — Basel, Switzerland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.